Mr William Hsieh

School of Allied Health and Human Performance

College of Health

Year	Citation
2023	Hull, A., Hsieh, W., Tieu, W., Bartholomeusz, D., Li, Y., & Bezak, E. (2023). In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer.. EJNMMI Radiopharm Chem, 8(1), 1-16. DOI Scopus4 WoS3 Europe PMC2
2023	Hull, A., Hsieh, W., Borysenko, A., Tieu, W., Bartholomeusz, D., & Bezak, E. (2023). Development of [225Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration.. EJNMMI Radiopharm Chem, 8(1), 1-18. DOI Scopus8 WoS9 Europe PMC5
2022	Hull, A., Li, Y., Bartholomeusz, D., Hsieh, W., Tieu, W., Pukala, T. L., . . . Bezak, E. (2022). Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma.. Cells, 11(19), 1-18. DOI Scopus5 WoS3 Europe PMC3
2021	Hull, A., Li, Y., Bartholomeusz, D., Hsieh, W., Escarbe, S., Ruszkiewicz, A., & Bezak, E. (2021). The expression profile and textural characteristics of C595-reactive MUC1 in pancreatic ductal adenocarcinoma for targeted radionuclide therapy. Cancers, 13(1, article no. 61), 1-16. DOI Scopus5 WoS5 Europe PMC5
2020	Hull, A., Li, Y., Bartholomeusz, D., Hsieh, W., Allen, B., & Bezak, E. (2020). Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma: A Review of the Current Status of Literature.. Cancers (Basel), 12(2), 29 pages. DOI Scopus12 WoS10 Europe PMC9